News – Page 937 – Endpoints News

Can we stop cancer cells from evolving and developing drug resistance? British scientists take a leaf out of the HIV ...

6 years ago

IsoPlexis bags $25M to stoke T cell therapy buzz; Collaboration between X4 and LLS; New CMO at Precision Biosciences

6 years ago

J&J polishes up its new list of late-stage blockbuster candidates — and cancer remains big

6 years ago

ImmunoGen shares tank (again) after the FDA nixes a shot at an OK for its armed antibody in wake of a failed PhIII

6 years ago

Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large

6 years ago

Vertex wagers $70M on Kymera and its new fascination with protein degradation

6 years ago

A top exec at struggling Biogen jumps ship for a new job

6 years ago

Pfizer, Merck KGaA clinch needed approval for Bavencio, directly competing against Keytruda in kidney cancer

6 years ago

Almost half of all new drug approvals in 2018 relied on one clinical trial

6 years ago

Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K

6 years ago

Daiichi Sankyo 'disappointed' as FDA experts spurn AML drug but vote in favor of rare tumor drug

6 years ago

Takeda forecasts $1.7B loss after Shire integration; Flagship's preclinical biotech Axcella closes IPO with $71M+ ...

6 years ago

Myovant's relugolix clears first uterine fibroids PhIII test, but competition from AbbVie/Neurocrine makes investors ...

6 years ago

Rejigging Merck KGaA partnership, Eliot Forster gains full control of the alpha in F-star's constellation

6 years ago

Boehringer Ingelheim flies the white flag as last holdout surrenders in war over a $20B AbbVie gold mine

6 years ago

Biopharma BD teams are speeding into the fast lane — cash in hand — as dealmaking continues to heat up in Q1 ...

6 years ago

Alzheimer’s R&D projects sidelined as Biogen’s aducanumab shock shakes researchers to the core of their beliefs

6 years ago

Regulatory intelligence: Update on regenerative medicine advanced therapies designations

6 years ago

What's taking the FTC so long? Roche won't say, but insists it will bag Spark on time — despite third delay

6 years ago

Solid Bio’s higher gene therapy dose for Duchenne MD runs smack into a fresh set of safety issues -- shares tumble

6 years ago

Minerva claims 'positive' PhII data on depression drug while skeptics push stock down

6 years ago

Bicycle sets terms for $65M IPO; Lilly's Cyramza wins fifth cancer approval

6 years ago

Microbiome upstart Vedanta gets an extra $18.5M in the bank, wrapping up $45.5 Series C round

6 years ago

Daiichi Sankyo faces FDA challenges on missing data, credibility and safety concerns in hunt for 2 new drug OKs

6 years ago

First page Previous page 934 935 936937938 939 940 Next page Last page